Nuclear transport modulators and uses thereof

Inventors

Sandanayaka, Vincent • Shechter, Sharon • Shacham, Sharon • McCauley, Dilara • Baloglu, Erkan

Assignees

Karyopharm Therapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10722497-B2

Patent

Publication Date

2020-07-28

Expiration Date


Abstract

Compounds of formula I: and pharmaceutically acceptable salts, hydrates, or solvates thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using such compounds and compositions to treat various disorders associated with CRM1 activity.

Core Innovation

The claimed invention provides Formula I compounds, or pharmaceutically acceptable salts, hydrates, or solvates thereof, that modulate CRM1 and nuclear transport with defined substituent alternatives for R1, R2, R3, and R4. A separate independent claim covers fifteen specified compound structures and their pharmaceutically acceptable salts, hydrates, or solvates. The examples describe morpholine-substituted hydrazide compounds as CRM1 inhibitors.

The compounds are presented for pharmaceutical compositions, combination therapies, and treatment of CRM1-associated disorders, including radiosensitization and wound healing. Reported examples demonstrate inhibition of CRM1-mediated nuclear export, elevated oral exposure measured as AUC, and lower brain-to-plasma ratios than comparator nuclear transport inhibitors. Pharmacological activity supports the claimed compounds across tumor, arthritis, obesity, and other disease models, while background problem details are not explicitly described in patent.

Claims Coverage

The claims include two independent claims covering two inventive features directed to Formula I compounds and fifteen specified compound structures, with dependent claims addressing pharmaceutical compositions and treatment methods.

Formula I compounds

Independent claim 1 covers a compound of Formula I, or a pharmaceutically acceptable salt, hydrate, or solvate thereof. It defines R1 as hydrogen or C1–C4 alkyl, R2 as O or S, R3 through specified cycloalkylamino, alkyl, heterocyclyl, or heteroaryl alternatives with stated substitution and ring-nitrogen requirements, and R4 as hydrogen or C1–C4 alkyl.

Specified compound structures

Independent claim 18 covers a compound represented by any one of fifteen specified structural formulas, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

The claims cover the defined Formula I compound genus and fifteen specified structural formulas, along with their pharmaceutically acceptable salts, hydrates, or solvates. Dependent claims specify narrower substituents, pharmaceutical compositions with a pharmaceutically acceptable carrier, and treatment methods for disorders associated with CRM1 activity.

Stated Advantages

The disclosed compounds inhibit CRM1-mediated nuclear export in the Rev-GFP assay.

Formula I compounds show higher mouse oral exposure, with reported AUCinf above 3,500 hr·ng/mL, and a lower brain-to-plasma ratio below 2.5 compared to comparator nuclear transport inhibitors.

Reduced tumor growth in Z-138 lymphoma and A549 xenografts.

Anti-arthritic activity, improved arthritis scores, joint swelling, paw histopathology, and reduced ear inflammation in inflammation models.

Altered food intake and body-weight measures in Zucker-rat and diet-induced-obesity studies.

Synergistic effects in combination with doxorubicin or bortezomib.

Radiosensitization for cancer therapy.

Reported activity in psoriasis, EAE, brain injury, and wound-healing models.

Documented Applications

Treatment of disorders associated with CRM1 activity, including cancer, inflammatory and autoimmune disorders, viral infections, neurodegenerative disorders, ophthalmic disorders, fibrotic disorders, and wound healing.

Treatment methods using a pharmaceutical composition comprising a claimed compound and a pharmaceutically acceptable carrier to treat disorders including lupus, multiple sclerosis, a muscular dystrophy, or amyotrophic lateral sclerosis.

Antitumor therapy, including activity documented in Z-138 lymphoma and A549 xenograft models.

Combination therapy, including combination anti-inflammatory therapy and synergistic combinations with doxorubicin or bortezomib.

Radiosensitization for cancer therapy.

Wound healing and scar reduction, including activity documented in a wound model.

Metabolic modulation, including effects documented on BMI and body-weight measures in Zucker-rat and diet-induced-obesity studies.

Treatment in rheumatoid arthritis, psoriasis, EAE, inflammation, brain injury, and MOG/CFA experimental disease models.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.